JPMorgan Chase & Co. Has $692,000 Stock Position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

JPMorgan Chase & Co. grew its position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 7,086.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 51,961 shares of the company's stock after acquiring an additional 51,238 shares during the period. JPMorgan Chase & Co. owned 0.20% of Eton Pharmaceuticals worth $692,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of ETON. Raymond James Financial Inc. acquired a new position in Eton Pharmaceuticals in the fourth quarter worth $147,000. Jane Street Group LLC bought a new stake in shares of Eton Pharmaceuticals during the third quarter valued at approximately $90,000. Hillsdale Investment Management Inc. acquired a new stake in shares of Eton Pharmaceuticals in the fourth quarter valued at approximately $226,000. Baader Bank Aktiengesellschaft bought a new position in Eton Pharmaceuticals in the 4th quarter valued at $373,000. Finally, Anchor Capital Advisors LLC acquired a new position in shares of Eton Pharmaceuticals during the fourth quarter valued at $805,000. 27.86% of the stock is owned by institutional investors and hedge funds.

Eton Pharmaceuticals Stock Performance

NASDAQ:ETON traded down $0.47 on Monday, reaching $16.87. The company's stock had a trading volume of 13,281 shares, compared to its average volume of 180,505. The business's 50-day moving average price is $14.28 and its two-hundred day moving average price is $13.32. Eton Pharmaceuticals, Inc. has a 1-year low of $3.18 and a 1-year high of $18.41. The firm has a market cap of $452.42 million, a PE ratio of -76.68 and a beta of 1.22.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last released its earnings results on Tuesday, March 18th. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.02). The firm had revenue of $11.65 million during the quarter, compared to analysts' expectations of $10.53 million. Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. As a group, sell-side analysts expect that Eton Pharmaceuticals, Inc. will post -0.14 EPS for the current year.

Wall Street Analyst Weigh In

ETON has been the topic of a number of research reports. HC Wainwright restated a "buy" rating and set a $33.00 target price on shares of Eton Pharmaceuticals in a research report on Wednesday, March 19th. Craig Hallum increased their price target on Eton Pharmaceuticals from $23.00 to $26.00 and gave the company a "buy" rating in a research note on Wednesday, March 19th. Finally, B. Riley reissued a "buy" rating and issued a $24.00 target price (up previously from $21.00) on shares of Eton Pharmaceuticals in a research note on Wednesday, March 19th.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.